M. Untch

443 total citations
14 papers, 52 citations indexed

About

M. Untch is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, M. Untch has authored 14 papers receiving a total of 52 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Cancer Research and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in M. Untch's work include Breast Cancer Treatment Studies (8 papers), Advanced Breast Cancer Therapies (5 papers) and HER2/EGFR in Cancer Research (4 papers). M. Untch is often cited by papers focused on Breast Cancer Treatment Studies (8 papers), Advanced Breast Cancer Therapies (5 papers) and HER2/EGFR in Cancer Research (4 papers). M. Untch collaborates with scholars based in Germany, Switzerland and Spain. M. Untch's co-authors include Claus Hanusch, Jens Huober, Jens‐Uwe Blohmer, Carsten Denkert, Peter A. Fasching, Christian Jackisch, Silvia Antolín, Julia Rey, Steffen Kahlert and Sibylle Loibl and has published in prestigious journals such as Annals of Oncology, European Journal of Cancer and Breast Cancer Research.

In The Last Decade

M. Untch

12 papers receiving 52 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Untch Germany	4	40	15	14	10	9	14	52
F. Marmé Germany	3	46 1.1×	19 1.3×	10 0.7×	12 1.2×	8 0.9×	4	58
M. Marty France	4	49 1.2×	10 0.7×	16 1.1×	9 0.9×	19 2.1×	4	83
Alice C. Durham United Kingdom	3	35 0.9×	9 0.6×	21 1.5×	10 1.0×	12 1.3×	3	46
Paula Podolski Croatia	4	21 0.5×	13 0.9×	15 1.1×	11 1.1×	22 2.4×	12	63
Vesna Glavicic Denmark	5	33 0.8×	21 1.4×	6 0.4×	20 2.0×	8 0.9×	11	50
Samuel M. Niman United States	5	56 1.4×	40 2.7×	9 0.6×	24 2.4×	16 1.8×	15	76
NL Busaidy United States	2	32 0.8×	11 0.7×	3 0.2×	10 1.0×	8 0.9×	2	67
Samira Bensfia Spain	3	54 1.4×	28 1.9×	9 0.6×	15 1.5×	12 1.3×	9	67
Sabela Recalde Spain	5	41 1.0×	12 0.8×	4 0.3×	22 2.2×	9 1.0×	14	58
Adrián Nervo Argentina	5	59 1.5×	35 2.3×	6 0.4×	13 1.3×	8 0.9×	12	71

Countries citing papers authored by M. Untch

Since Specialization

Citations

This map shows the geographic impact of M. Untch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Untch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Untch more than expected).

Fields of papers citing papers by M. Untch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Untch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Untch. The network helps show where M. Untch may publish in the future.

Co-authorship network of co-authors of M. Untch

This figure shows the co-authorship network connecting the top 25 collaborators of M. Untch. A scholar is included among the top collaborators of M. Untch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Untch. M. Untch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Erber, Ramona, Paul Gaß, Alexander Hein, et al.. (2025). Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers. Breast Cancer Research. 27(1). 13–13.

Untch, M., et al.. (2025). 228P Ribociclib (RIB) in early breast cancer (eBC): Pharmacokinetic (PK) assessment and exposure-response analysis. ESMO Open. 10. 104782–104782.

Sinn, Bruno V., M. Untch, Thomas Karn, et al.. (2024). On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer. Breast Cancer Research. 26(1). 138–138. 1 indexed citations

Reinisch, Mattea, Jens‐Uwe Blohmer, Theresa Link, et al.. (2022). 94P Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC). Annals of Oncology. 33. S166–S167. 1 indexed citations

Loibl, Sibylle, Mattea Reinisch, Carsten Denkert, et al.. (2022). 200TiP A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)- GeparPiPPa. Annals of Oncology. 33. S627–S627. 2 indexed citations

Dent, Rebecca, Javier Cortés, Lajos Pusztai, et al.. (2022). 135MO HRQoL with neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522. Annals of Oncology. 33. S600–S601. 5 indexed citations

Marmé, Frederik, Claus Hanusch, Jenny Furlanetto, et al.. (2022). 58O Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment. Annals of Oncology. 33. S148–S149. 26 indexed citations

Hartmann, Sylvia, Jana de Boniface, Oreste Gentilini, et al.. (2022). 120P AXSANA (AXillary Surgery After NeoAdjuvant Treatment) EUBREAST-3: An international prospective multicenter cohort study to evaluate different surgical methods of axillary staging in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy (NCT04373655). Annals of Oncology. 33. S178–S179. 1 indexed citations

Karn, Thomas, Karsten E. Weber, Uwe Holtrich, et al.. (2020). 127O Tumour mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Annals of Oncology. 31. S58–S58. 2 indexed citations

10.

Jochum, Frank, Barbara Schmidt, K. Schunk, et al.. (2008). Quality of care of VLBW neonates: relationship between unit volume and outcome is different between metropolitan and rural regions. Acta Paediatrica. 97(10). 1470–1474. 3 indexed citations

11.

Langer, Bernd, M Muscholl, M. Pauschinger, et al.. (2004). Prospective investigation of the significance of cardiac markers, NT-pro Brain Natriuretic Peptide (NT-proBNP) and Troponin T (TnT), in the Hercules study of epirubicin/cyclophosphamide with or without trastuzumab (Herceptin®). European Journal of Cancer Supplements. 2(3). 143–143. 2 indexed citations

12.

Minckwitz, Gϋnter von, Serban Dan Costa, Peter Dall, et al.. (2002). Evidence-Based Recommendations on Treating Locoregional and Distant Metastases of Carcinomas of the Breast. Zentralblatt für Gynäkologie. 124(5). 284–292. 4 indexed citations

13.

Kahlert, Steffen, et al.. (1999). Prognostic impact of extended extracapsular component (EEC) in involved lymph nodes (LN) in primary breast cancer (BC). European Journal of Cancer. 35. S89–S89. 4 indexed citations

14.

Lampe, Björn, et al.. (1993). Adenokarzinom und Adenose der Vagina. Geburtshilfe und Frauenheilkunde. 53(5). 308–313. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact